预约演示

更新于：2025-05-07

CACNG8

更新于：2025-05-07

基本信息

别名

CACNG6、CACNG8、calcium voltage-gated channel auxiliary subunit gamma 8

+ [4]

简介

Regulates the activity of L-type calcium channels that contain CACNA1C as pore-forming subunit (By similarity). Regulates the trafficking and gating properties of AMPA-selective glutamate receptors (AMPARs). Promotes their targeting to the cell membrane and synapses and modulates their gating properties by slowing their rates of activation, deactivation and desensitization and by mediating their resensitization. Does not show subunit-specific AMPA receptor regulation and regulates all AMPAR subunits.

关联

项与 CACNG8 相关的药物

CERC-611

靶点

CACNG8

作用机制

CACNG8 inhibitors

在研机构

ES Therapeutics Australia Pty Ltd

原研机构

Eli Lilly & Co. [+1]

在研适应症

特发性震颤 [+1]

非在研适应症

疼痛 [+1]

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

RAP-219

靶点

CACNG8

作用机制

CACNG8 modulators

在研机构

Rapport Therapeutics, Inc.

原研机构

Rapport Therapeutics, Inc.

在研适应症

癫痫部分性发作 [+3]

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

11C-TARP-2105

碳[11C]TARP-2105

靶点

CACNG8

作用机制

CACNG8 inhibitors

在研机构

南方科技大学 [+2]

原研机构

The General Hospital Corp.

在研适应症

中枢神经系统疾病

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

项与 CACNG8 相关的临床试验

NCT06377930

/ Recruiting临床2期

A Phase 2A, Multicenter, Open-label Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal Epilepsy.

开始日期2024-10-10

申办/合作机构

Rapport Therapeutics, Inc.

CTIS2024-512151-21-00

/ Not yet recruiting临床1期

- RAP-219-103

开始日期2024-06-19

申办/合作机构

Rapport Therapeutics, Inc.

NCT05234762

/ Recruiting临床2期

A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ES-481 in Adult Patients With Essential Tremors

This Pilot Phase 2A study will investigate the safety, tolerability, and pharmacokinetics (PK) of ES-481 in adult patients with essential tremor.

开始日期2021-11-21

申办/合作机构

ES Therapeutics Australia Pty Ltd

100 项与 CACNG8 相关的临床结果

登录后查看更多信息

100 项与 CACNG8 相关的转化医学

登录后查看更多信息

0 项与 CACNG8 相关的专利（医药）

登录后查看更多信息

项与 CACNG8 相关的文献（医药）

2025-03-01·eneuro

Aniracetam Ameliorates Attention Deficit Hyperactivity Disorder Behavior in Adolescent Mice

Article

作者: Cui, Jie ; Bai, Hui ; Bai, Wan-Jun ; Sun, Xiao-Li ; Zhang, Wei

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that affects 8–12% of children globally. Hyperactivity-related behaviors, as well as inattention and impulsivity, are regarded as the nuclear symptoms of ADHD. At present, its etiologies and risk factors are unknown. Previous research linked TARP γ-8 deficiency to ADHD-like behaviors in mice, including hyperactivity, impulsivity, and memory deficits. Aniracetam, a nootropic drug, enhances cognition by modulating cholinergic activity and glutamate receptors, offering neuroprotective effects. This study examined TARP γ-8 knockout (KO) mice at 4 and 8 weeks, assessing behaviors through locomotor activity, cliff avoidance, novel object recognition, and contextual fear conditioning tests. TARP γ-8 KO mice exhibited hyperactivity, reduced recognition memory, and impaired short-term memory and long-term memory. Aniracetam administration improved these behavioral deficits, suggesting its potential as a therapeutic agent for ADHD. The findings align with ADHD’s pathophysiology, resembling the neurological impairments in TARP γ-8 KO mice. Aniracetam shows promise as a novel treatment for ADHD symptoms, highlighting its therapeutic value.

2025-02-01·American Journal of Hematology

Blood Plasma Methylated DNA Markers in the Detection of Lymphoma: Discovery, Validation, and Clinical Pilot

Article

作者: Katerov, Slava ; Graham, Rondell P. ; Jevremovic, Dragan ; Novak, Anne J. ; Burger, Kelli N. ; Berger, Calise K. ; Mahoney, Douglas W. ; O'Connell, Maria C. ; Taylor, William R. ; Cerhan, James R. ; Witzig, Thomas E. ; Allawi, Hatim T. ; Dao, Linda N. ; Foote, Patrick H. ; Kisiel, John B. ; Hennek, Jacquelyn ; Bamlet, William R. ; Doering, Karen A. ; Devens, Mary E. ; Arndt, Jacquelyn R.

ABSTRACTLymphoma is one of the leading causes of cancer and cancer deaths and yet has not been amenable to population screening. The role of methylated DNA markers (MDMs) in the detection of lymphoma has not been extensively studied. We aimed to discover, validate, and test tissue–derived MDMs of lymphoma in archival plasma specimens. Reduced representation bisulfite sequencing (RRBS) was performed on a discovery set of frozen tissues. MDMs identified were converted to methylation–specific PCR assays and validated on independent formalin–fixed, paraffin‐embedded (FFPE) tissues. Target enrichment long–probe quantitative‐amplified signal (TELQAS) assays were developed and assayed in plasma–extracted, bisulfite‐converted DNA from independent treatment‐naïve lymphoma patients and healthy controls. Prediction of cancer status was modeled using random forest model with in silico cross‐validation. After discovery and validation in tissue, 16 TELQAS assays (ZNF503, VWA5B1, HOXA9, GABRG3, ITGA5, MAX.chr17.7190, BNC1, CDK20, MAX.chr4.4069, TPBG, DNAH14, SYT6, CACNG8, FAM110B, ADRA1D, and NRN1) were selected for testing in plasma. These detected 78% (95% CI, 74%–82%) of lymphoma cases at 90% specificity. Excluding marginal zone and T‐cell lymphomas, sensitivity increased to 84% (80%–88%). MDMs in plasma show promise to detect lymphoma and are candidates for inclusion in multi‐cancer detection studies.

2024-06-01·Pharmacological Research

Baicalin restore intestinal damage after early-life antibiotic therapy: the role of the MAPK signaling pathway

Article

作者: Zhang, Shunfen ; Zhang, Hongfu ; Chen, Liang ; Lv, Huiyuan ; Zhong, Ruqing ; Tang, Shanlong ; Liu, Zhengqun ; Cai, Xueying

Antibiotic related intestinal injury in early life affects subsequent health and susceptibility. Here, we employed weaned piglets as a model to investigate the protective effects of baicalin against early-life antibiotic exposure-induced microbial dysbiosis. Piglets exposed to lincomycin showed a marked reduction in body weight (p < 0.05) and deterioration of jejunum intestinal morphology, alongside an increase in antibiotic-resistant bacteria such as Staphylococcus, Dolosicoccus, Escherichia-Shigella, and Raoultella. In contrast, baicalin treatment resulted in body weights, intestinal morphology, and microbial profiles that closely resembled those of the control group (p > 0.05), with a significant increase in norank_f_Muribaculaceae and Prevotellaceae_NK3B31_group colonization compared with lincomycin group (p < 0.05). Further analysis through fecal microbial transplantation into mice revealed that lincomycin exposure led to significant alterations in intestinal morphology and microbial composition, notably increasing harmful microbes and decreasing beneficial ones such as norank_Muribaculaceae and Akkermansia (p < 0.05). This shift was associated with an increase in harmful metabolites and disruption of the calcium signaling pathway gene expression. Conversely, baicalin supplementation not only counteracted these effects but also enhanced beneficial metabolites and regulated genes within the MAPK signaling pathway (MAP3K11, MAP4K2, MAPK7, MAPK13) and calcium channel proteins (ORA13, CACNA1S, CACNA1F and CACNG8), suggesting a mechanism through which baicalin mitigates antibiotic-induced intestinal and microbial disturbances. These findings highlight baicalin's potential as a plant extract-based intervention for preventing antibiotic-related intestinal injury and offer new targets for therapeutic strategies.